- Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 Years
-
Yoo BW, Kim CO, Izu A, Arora AK, Heijnen E
- KMID: 2429933
- Infect Chemother.
- 2018 Dec;50(4):301-310.
- doi: 10.3947/ic.2018.50.4.301
BACKGROUD: Influenza vaccination is recommended for adults aged ≥65 years as they are at high risk of significant morbidity and mortality. This open-label, multicenter, post-marketing surveillance study assessed the safety... -
- CITED
-
- Close
- SHARE
-
- Close
